Apalutamide–ADT indication expanded in Europe
medwireNews: Men in Europe with metastatic castration-sensitive prostate cancer may now be treated with the anti-androgen agent apalutamide during androgen deprivation therapy (ADT).
The EMA previously granted approval for use of the combination in men with nonmetastatic castration-resistant prostate cancer at high risk for distant disease based on findings from the SPARTAN trial, and both indications have already been approved by the US FDA.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2020 Springer Healthcare part of the Springer Nature group